The exercise period for Alligator’s warrants of series TO 6 took place between August 17 and 31, 2023.
Q2 2023 Earnings call
Alligator hosted a conference call on July 13 at 4 p.m. CEST/ 10 a.m. ET for investors, analysts and media, where CEO Søren Bregenholt, CFO Marie Svensson, and CMO Sumeet Ambarkhane presented and commented on the Q2 interim report, which was followed by a Q&A session. The call can be accessed through Alligator’s YouTube channel.
LATEST NEWS
Alligator Bioscience Presents New Data Demonstrating Durable Response and Encouraging Anti-Tumor Activity of Lead Asset Mitazalimab
Clinical and preclinical data from three presentations further demonstrate mitazalimab's ability to activate the immune system and enha …
Alligator Bioscience Announces Publication Highlighting Pharmacodynamic Data from Mitazalimab Phase 1 Study in Scientific Journal “Cells”
Data demonstrate that mitazalimab induces transcriptomic alterations consistent with immune activation Data reinforce mitazalimab's mod …
Alligator receives approximately SEK 13.8 million through the exercise of warrants of series TO 6
The exercise period for warrants series TO 6 in Alligator Bioscience AB (publ) (“Alligator” or the “Company”) ended on 31 August 2023. A tot …